Australia's largest stock trading and investment forum Australia's #1 stock forum

PER

0.00%

10.5¢ percheron therapeutics limited

For General Information, page-2408

First 2408 Last

Share
Profile

Follow
nottawombat

6,257 Posts.

582

23/08/23

16:12

Post #: 69505837
Share

Originally posted by BoomCrashOffera: ↑

I’m wary of treading into medical science comparisons, but some differences between ANP (ATL1102) and CAPR (CAP1002) imo on a cursory analysis.

1. CAP1002 is in phase three (pivotal) trial stage (HOPE-3) and has 4 years of data on their P2 trial (one year blinded with placebo, a gap year and then 2 years of OLE).

2. CAP1002 P2 and P3 trials include placebo group

3. CAP1002 - Intravenous doses every 3 months versus ATL1102 injections every week

4. CAP102 Results include cardio function as well as PUL 2.0. 6 of 9 boys had improved cardio function after two year OLE (open label extension) in P2 trial. ATL1102 is yet to prove it can affect heart function. I recall reading somewhere that this was a challenge with antisense oligonucleotides. Someone with more medical knowledge could correct me here.

5. Correct me if I’m wrong but CAP1002 trials cover both ambulant and non-ambulant boys

6. No toxicity issues and a US pathway well established. In ongoing meetings with FDA that they will soon publish minutes of the latest.

7. They create, own and develop their drugs. No licensing and/or payaway or limit to creating new drugs.

8. They have a distribution agreement in place for US and Japan markets with Nippon Shinyaku.

9. CAPR have 77 employees, 8 directors and 10 scientific advisors.

Apart from the above, ATL1102 could be a better treatment.

Expand

I think you forgot to add that the facility to manufacture is now up and running

ANP Price at posting: 5.2¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1,127 more messages in this thread...

First 2408 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $94.66M

Open	High	Low	Value	Volume
10.5¢	10.5¢	9.8¢	$58.09K	574.8K

Buyers (Bids)

No.	Vol.	Price($)
1	38503	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	194063	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.099
2	108491	0.098
1	30927	0.097
1	10004	0.096
3	162157	0.095

Price($)	Vol.	No.
0.105	194063	5
0.110	254663	3
0.115	1334300	6
0.120	381142	9
0.125	110429	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PER (ASX) Chart

For General Information, page-2408

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

For General Information, page-2408

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News